PT - JOURNAL ARTICLE AU - Ferretti, Luca AU - Wymant, Chris AU - Kendall, Michelle AU - Zhao, Lele AU - Nurtay, Anel AU - Abeler-Dörner, Lucie AU - Parker, Michael AU - Bonsall, David AU - Fraser, Christophe TI - Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing AID - 10.1101/2020.03.08.20032946 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.08.20032946 4099 - http://medrxiv.org/content/early/2020/03/31/2020.03.08.20032946.short 4100 - http://medrxiv.org/content/early/2020/03/31/2020.03.08.20032946.full AB - The newly emergent human virus SARS-CoV-2 is resulting in high fatality rates and incapacitated health systems. Preventing further transmission is a priority. We analysed key parameters of epidemic spread to estimate the contribution of different transmission routes and determine requirements for case isolation and contact-tracing needed to stop the epidemic. We conclude that viral spread is too fast to be contained by manual contact tracing, but could be controlled if this process was faster, more efficient and happened at scale. A contact-tracing App which builds a memory of proximity contacts and immediately notifies contacts of positive cases can achieve epidemic control if used by enough people. By targeting recommendations to only those at risk, epidemics could be contained without need for mass quarantines (‘lock-downs’) that are harmful to society. We discuss the ethical requirements for an intervention of this kind.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Li Ka Shing Foundation. The funder played no role in study conception or execution.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript or the supplementary material.